Colpermin in colonoscopy

Premedication with Peppermint oil capsules (Colpermin®) in colonoscopy: A Double blind placebo-controlled randomized trial study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107056957N1

Enrollment

Registered

2011-07-16

Start date

2008-08-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with digestive diseases who need colonoscopy. Crohn's disease [regional enteritis] , Ulcerative colitis , Other noninfective gastroenteritis and colitis, Vascular disorders of intestine , Diverticular disease of intestine , Other diseases of anus and rectum , Other diseases of digestive system

Interventions

Intervention 1: Taking 2 colpermin (187 mg) capsules 4 hour before colonoscopy. Intervention 2: Taking 2 placebo capsules (filling with lactulose) 4 hour before colonoscopy.

Placebo

Treatment - Drugs

Taking 2 colpermin (187 mg) capsules 4 hour before colonoscopy

Taking 2 placebo capsules (filling with lactulose) 4 hour before colonoscopy

Eligibility

Sex/Gender

All

Age

18 Years to 81 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients who have indication for colonoscopy by expert physician; age more than 18 and signing the informed consent. Exclusion criteria: Patients that total colonoscopy is not possible for them (due to obstruction by tumor or being high risk for perforation as in severe colitis or history of colectomy); pregnant and lactating women, and peppermint allergy history

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: after colonoscopy. Method of measurement: numerical rating scale.;Time required for intubation to the cecum and the total procedure time. Timepoint: after colonoscopy. Method of measurement: minites.;Colon spasm. Timepoint: after colonoscopy. Method of measurement: numerical rating scale for spasm.	—

Secondary

Measure	Time frame
Drug adverse effect. Timepoint: before and after colonoscopy. Method of measurement: questionnaire.;Bowel preparation. Timepoint: after colonoscopy. Method of measurement: numerical rating scale for bowel preparation.;Colonoscopist satisfaction. Timepoint: after colonoscopy. Method of measurement: numerical rating scale for colonoscopist satisfaction.;Patient willingness to repeat colonoscopy with the present method. Timepoint: after colonoscopy. Method of measurement: questionnaire.	—

Measure

Time frame

Drug adverse effect. Timepoint: before and after colonoscopy. Method of measurement: questionnaire.;Bowel preparation. Timepoint: after colonoscopy. Method of measurement: numerical rating scale for bowel preparation.;Colonoscopist satisfaction. Timepoint: after colonoscopy. Method of measurement: numerical rating scale for colonoscopist satisfaction.;Patient willingness to repeat colonoscopy with the present method. Timepoint: after colonoscopy. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Samaneh Khanpour Ardestani

Isfahan University of Medi

khanpour@med.mui.ac.ir+98 31 1792 3060

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026